HI
CERE

HBK Investments’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

HBK Investments’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,039,137
Closed -$42.5M – 215
2024
Q2 		$42.5M Buy
1,039,137
+679,419
+189% +$28.3M 0.19% 30
2024
Q1 		$15.2M Buy
+359,718
New +$15.1M 0.07% 54

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HBK Investments's CERE Position: Q3 2024 in Review

HBK Investments sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,039,137 shares — an estimated $42.5M sold.

HBK Investments first reported a position in CERE in Q1 2024 and held it in 2 quarters. The position peaked at $42.5M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • HBK Investments reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • HBK Investments sold 1,039,137 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $42.5M.
  • HBK Investments first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
  • HBK Investments's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $42.5M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on HBK Investments's 13F filing for Q3 2024, filed 14 Nov 2024.